Article Abstract

Which criteria should we use to evaluate the efficacy of immunecheckpoint inhibitors?

Authors: Yuki Kataoka, Katsuya Hirano

Abstract

Immune-checkpoint inhibitors (ICI) have innovated the treatment of many different types of advanced cancer. Two important distinctions between ICI and other modalities are durable response (DR) and pseudoprogression (1,2).